| Title | Continuous Clindamycin Infusion: an Innovative Approach to Treating Bone and Joint Infection. | | Author(s) | Zeller V, Dzeing-Ella A, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N | | Institution | Service de Chirurgie Osseuse et Traumatologique, Service de Médecine Interne et Rhumatologie, Centre de Référence des Infections Ostéo-Articulaires, Laboratoire de Biologie Médicale, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d'Avron, 75020 Paris, France; Laboratoire de Microbiologie, Groupe Hospitalier Paris Saint-Joseph, 68, rue des Plantes, 75014 Paris, France. | | Source | Antimicrob Agents Chemother 2009 Oct 19. | | Abstract | Feasibility, safety and efficacy of prolonged, continuous, intravenous clindamycin therapy were retrospectively evaluated for 70 patients treated for bone and joint infections, 40% as outpatients. Median treatment duration was 40 days, median daily clindamycin dose was 2400 mg and 3 moderate-grade adverse events occurred. Median serum clindamycin concentrations on days 3-14 and 8-28 were 5 and 6.2 mg/liter, respectively; the median concentration was significantly lower (P<0.02) in patients treated with rifampin (5.3 mg/liter) versus without rifampin (8.9 mg/liter). Among 53 patients with a median [range] follow-up of 30 [24-53] months, 49 (92%) were considered cured (1 relapse, 3 reinfections). | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19841148 |
|
